Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized clinical study to evaluate the safety and efficacy of using the Beta 3 agonist drug (Mirabegron) combined with standard behavioral therapy in comparison to using the anticholinergic drug (Solifenacin) combined with behavioral therapy, for children with non-neurogenic voiding dysfunction refractory to behavioral therapy alone, using improvement of dysfunctional voiding symptom score as a primary measurement of efficacy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mansoura University
• Treatments: Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-3 Receptor Agonists; Cholinergic Antagonists; Solifenacin Succinate

Criteria

Inclusion Criteria:

• Children with non-neurogenic voiding dysfunction predominantly filling phase dysfunctions or OAB, refractory to behavioral therapy as a primary monotherapy, with dysfunctional voiding symptom score of ≥6 for females and ≥9 for males, between the age of 5 & 18 years old.

Exclusion Criteria:

• Neurogenic or anatomical bladder problems.

• Patients with contraindications to Beta 3 agonists or anticholinergic drugs.